Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2023 | 33 | 3.860 |
Why?
|
| Multiple Myeloma | 6 | 2023 | 320 | 3.290 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 17 | 2.250 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 253 | 2.180 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 124 | 2.140 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 259 | 1.370 |
Why?
|
| Puerto Rico | 10 | 2023 | 227 | 1.230 |
Why?
|
| Periodontitis | 3 | 2022 | 16 | 1.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 163 | 0.870 |
Why?
|
| Occult Blood | 1 | 2023 | 15 | 0.860 |
Why?
|
| SEER Program | 2 | 2021 | 63 | 0.830 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 72 | 0.810 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 33 | 0.810 |
Why?
|
| Paraproteinemias | 1 | 2022 | 18 | 0.800 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 72 | 0.740 |
Why?
|
| Chlamydia trachomatis | 1 | 2020 | 57 | 0.680 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 77 | 0.660 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2024 | 48 | 0.610 |
Why?
|
| Adult | 12 | 2024 | 15702 | 0.590 |
Why?
|
| Hypertension | 1 | 2023 | 598 | 0.570 |
Why?
|
| Aged | 11 | 2023 | 13268 | 0.560 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 2460 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 315 | 0.530 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 328 | 0.530 |
Why?
|
| United States | 8 | 2023 | 7480 | 0.500 |
Why?
|
| Humans | 21 | 2024 | 59183 | 0.500 |
Why?
|
| Disease Progression | 3 | 2023 | 1038 | 0.450 |
Why?
|
| Middle Aged | 10 | 2023 | 16204 | 0.430 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 826 | 0.410 |
Why?
|
| Papillomaviridae | 2 | 2022 | 59 | 0.390 |
Why?
|
| Female | 13 | 2023 | 30761 | 0.370 |
Why?
|
| Male | 10 | 2022 | 27440 | 0.340 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 781 | 0.310 |
Why?
|
| Comorbidity | 2 | 2022 | 1084 | 0.300 |
Why?
|
| Incidence | 2 | 2020 | 1232 | 0.260 |
Why?
|
| Chronic Disease | 2 | 2024 | 731 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 5060 | 0.210 |
Why?
|
| Multimorbidity | 1 | 2023 | 38 | 0.210 |
Why?
|
| Periodontal Diseases | 1 | 2022 | 15 | 0.210 |
Why?
|
| Young Adult | 3 | 2022 | 4313 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 39 | 0.200 |
Why?
|
| Immunization Programs | 1 | 2022 | 17 | 0.200 |
Why?
|
| Mouthwashes | 1 | 2021 | 6 | 0.200 |
Why?
|
| Age Factors | 3 | 2021 | 1518 | 0.200 |
Why?
|
| Medicare | 2 | 2023 | 601 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 145 | 0.190 |
Why?
|
| Insurance, Health | 1 | 2022 | 141 | 0.190 |
Why?
|
| Microbiota | 1 | 2022 | 106 | 0.190 |
Why?
|
| Outpatients | 1 | 2022 | 131 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 59 | 0.180 |
Why?
|
| Social Class | 1 | 2021 | 123 | 0.180 |
Why?
|
| Tooth Loss | 1 | 2020 | 8 | 0.180 |
Why?
|
| Europe | 1 | 2021 | 182 | 0.180 |
Why?
|
| Sex Factors | 2 | 2021 | 960 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2021 | 60 | 0.180 |
Why?
|
| Antigens | 1 | 2021 | 146 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 47 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 336 | 0.170 |
Why?
|
| Adolescent | 2 | 2021 | 5912 | 0.170 |
Why?
|
| Prevalence | 2 | 2020 | 1278 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 222 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 453 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 373 | 0.160 |
Why?
|
| Risk Factors | 4 | 2022 | 4995 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 446 | 0.160 |
Why?
|
| Cause of Death | 1 | 2019 | 200 | 0.150 |
Why?
|
| Mortality | 1 | 2019 | 159 | 0.150 |
Why?
|
| Tetracycline | 1 | 2017 | 20 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1056 | 0.150 |
Why?
|
| Inflammation | 2 | 2022 | 1100 | 0.150 |
Why?
|
| Hair Follicle | 1 | 2017 | 29 | 0.150 |
Why?
|
| Neural Crest | 1 | 2017 | 29 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 787 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 738 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1203 | 0.140 |
Why?
|
| Melanocytes | 1 | 2017 | 78 | 0.140 |
Why?
|
| Embryonic Stem Cells | 1 | 2017 | 150 | 0.140 |
Why?
|
| Diet | 1 | 2021 | 635 | 0.130 |
Why?
|
| Smoking | 1 | 2021 | 831 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 801 | 0.130 |
Why?
|
| Aging | 1 | 2020 | 722 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 630 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1019 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1124 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1186 | 0.100 |
Why?
|
| United States Virgin Islands | 1 | 2023 | 2 | 0.050 |
Why?
|
| Guam | 1 | 2023 | 3 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2022 | 7 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2022 | 121 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 41 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 56 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 691 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 473 | 0.040 |
Why?
|
| Oral Health | 1 | 2020 | 73 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 398 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 1564 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2017 | 5 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 704 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2017 | 25 | 0.040 |
Why?
|
| Lac Operon | 1 | 2017 | 26 | 0.040 |
Why?
|
| Pigmentation | 1 | 2017 | 25 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2017 | 65 | 0.040 |
Why?
|
| Models, Animal | 1 | 2017 | 219 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 247 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 772 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 667 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 655 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1252 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2082 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 669 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1218 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1219 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 5956 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3182 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 10235 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 19556 | 0.010 |
Why?
|
Castaneda Avila's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(116)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_